Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

-Capricor to Receive $15 Million Equity Investment at a 20$20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a DoubleDigit Percentage of Product Revenue- -Upfront Payment and Investment Extends Cash Runway into 2026- -Potential Milestones from Combined Distribution Agreements Now Total approximately$1.5 Billion- -Capricor Preparing to Meet with EMA to Discuss European Expansion for Deramiocel- SAN DIEGO, Sept. 17, 2024 (GL ...